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Abstract
1q21.1 hemizygous microdeletion is a copy number variant leading to eightfold increased risk of schizophrenia. In
order to investigate biological alterations induced by this microdeletion, we generated a novel mouse model (Df
(h1q21)/+) and characterized it in a broad test battery focusing on schizophrenia-related assays. Df(h1q21)/+ mice
displayed increased hyperactivity in response to amphetamine challenge and increased sensitivity to the disruptive
effects of amphetamine and phencyclidine hydrochloride (PCP) on prepulse inhibition. Probing of the direct
dopamine (DA) pathway using the DA D1 receptor agonist SKF-81297 revealed no differences in induced locomotor
activity compared to wild-type mice, but Df(h1q21)/+ mice showed increased sensitivity to the DA D2 receptor agonist
quinpirole and the D1/D2 agonist apomorphine. Electrophysiological characterization of DA neuron ﬁring in the
ventral tegmental area revealed more spontaneously active DA neurons and increased ﬁring variability in Df(h1q21)/+
mice, and decreased feedback reduction of DA neuron ﬁring in response to amphetamine. In a range of other assays,
Df(h1q21)/+ mice showed no difference from wild-type mice: gross brain morphology and basic functions such as
reﬂexes, ASR, thermal pain sensitivity, and motor performance were unaltered. Similarly, anxiety related measures,
baseline prepulse inhibition, and seizure threshold were unaltered. In addition to the central nervous system-related
phenotypes, Df(h1q21)/+ mice exhibited reduced head-to tail length, which is reminiscent of the short stature
reported in humans with 1q21.1 deletion. With aspects of both construct and face validity, the Df(h1q21)/+ model may
be used to gain insight into schizophrenia-relevant alterations in dopaminergic transmission.
Introduction
Schizophrenia symptoms are commonly divided into
three domains: positive symptoms (hallucinations, delu-
sions), negative symptoms (deﬁcits in speech, motivation,
and social functioning), and cognitive deﬁcits. The arguably
most prominent theory of the biology of schizophrenia, the
dopamine (DA) hypothesis, is largely based on pharma-
cological observations: positive symptoms in patients are
reduced by DA D2 receptor antagonists, which is the key
mechanism of action of all marketed drugs for treatment
of schizophrenia1. Amphetamine and other compounds
that increase DA release increase psychotic symptoms in
schizophrenia patients at doses that have no psychotropic
effects in healthy volunteers2, while higher doses or pro-
longed exposure can induce psychotic symptoms in
healthy volunteers3. This has led to the hypothesis that
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increased DA transmission in the striatum underlies
positive symptoms in schizophrenia, and is further sup-
ported by imaging data suggesting both increased striatal
DA and pre-synaptic DA synthesis capacity in patients
with schizophrenia4,5. Furthermore, recent genome-wide
association studies have shown that single-nucleotide
polymorphisms (SNPs) in the D2 receptor are linked to
schizophrenia risk6. In an extension of this hypothesis,
cortical hypodopaminergia has been proposed to underlie
positive and negative symptoms, but the evidence is
sparser, although recent imaging data lend support7,8.
While some insight into transmitter alterations has been
gained, there is at present no coherent understanding of
the etiology that may underlie these changes.
Animal models with construct validity are key tools in the
investigation of mechanisms underlying human diseases—
and in the search for new drugs. Schizophrenia is a strongly
heritable disease6, so genetic animal models constitute an
obvious tool for investigating the mechanisms underlying
this disease. However, until recently only a few reproducible
genetic links had been found. In 2008, it became clear that
certain rare recurrent hemizygous copy number variants
(CNVs) strongly increase the risk of developing schizo-
phrenia9,10. Since then, the list has been expanded to at least
eight CNVs that increase the risk of developing schizo-
phrenia with genome-wide signiﬁcance11,12. These CNVs
provide the arguably best available starting points for the
development of genetic animal models of schizophrenia,
since their large impact on schizophrenia risk increases the
chance of ﬁnding relevant phenotypes. Furthermore, unlike,
for example, schizophrenia-associated SNPs, the relevant
corresponding mouse alterations for CNV models are clear
—deletion or duplication of a speciﬁc set of genes.
The human 1q21.1 microdeletion was found to be
associated with eightfold increased risk of schizophrenia in
20089,10, and this association has been replicated in several
studies11,12. The CNV involves hemizygous deletion of
nine genes in the distal part of 1q21.1 (Fig. 1a). In addition
to increased risk of schizophrenia, it is also linked to an
increased risk of attention deﬁcit hyperactivity disorder
(ADHD), developmental delay, and autism spectrum dis-
orders13,14. Furthermore, the deletion has been associated
with congenital heart defects, facial abnormalities, micro-
cephaly, and short stature14–16. Increased risk of additional
disorders or syndromic presentation is a shared feature for
schizophrenia-associated CNVs, and the risk of additional
disorders is also common for SNPs associated with schi-
zophrenia17,18. While the 1q21.1 microdeletion strongly
increases the risk of schizophrenia and other conditions,
some carriers are apparently clinically unaffected by the
deletion14.
In this paper, we report the generation of the ﬁrst
1q21.1 microdeletion mouse model Df(h1q21)/+, with a
functional and pharmacological characterization focusing
on schizophrenia-related traits. We ﬁnd selective altera-
tions in DA transmission and examine how these phe-
nomena depend on pre-synaptic and post-synaptic
dopaminergic function. In addition, we ﬁnd somatic
characteristics in the Df(h1q21)/+ mice that seem to
recapitulate clinical observations in human carriers.
Overall, these ﬁndings suggest that the Df(h1q21)/+
mouse model constitutes a valuable tool for investigating
the functional impact of excessive or dysregulated DA
transmission, and putative disease mechanisms under-
lying positive symptoms of schizophrenia.
Materials and methods
Animals
The Df(h1q21)/+ mouse line was generated by Taco-
nicArtemis (Köln, Germany). Two targeting vectors were
generated using bacterial artiﬁcial chromosome clones
from the C57BL/6J RPCI-23 bacterial artiﬁcial chromo-
some library and transfected into TaconicArtemis C57BL/
Fig. 1 Construct similarities in Df(h1q21)/+ mice and human
1q21.1 deletion carriers. a Overview of the deleted region in man
(1q21.1) and the corresponding orthologous region in mouse (3qF2.2).
The mouse deletion spans from a breakpoint upstream of exon 11 of the
Gpr89 gene and a breakpoint downstream of exon 7 of the Prkab2 gene
(see Supplement 1 for details). The lists are based on the human library
GRCh38/hg38 and the mouse library GRCm38/mm10 from the UCSC
database. Only annotated RefSeq genes are shown. b mRNA expression
changes in tissue from frontal cerebral cortex measured by microarray in
14-week-old Df(h1q21)/+ mice compared with their wild-type littermates.
The number of genes tested upstream and downstream of the deletion
was increased until transcripts could be detected. Gja8 and Cd160 were
below the detection limit in wild-type mouse brain. n = 6 Df(h1q21)/+
and 12 wild-type littermates. Data presented as median ± SEM. ***p<
0.001 following t-test with Welch’s correction of gene expression in Df
(h1q21)/+ compared to wild-type mice. c Head-to-tail base length. n =
233–235 mice/group. Data presented as means ± SEM. ***p< 0.001
following Mann–Whitney test. **p< 0.01
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6N Tac embryonic stem cell line. The ﬁrst vector intro-
duced a loxP site upstream of the Gpr89 gene. The second
vector introduced a loxP site downstream of Prkab2.
Homologous recombinant clones were isolated and the
0.8 megabase region on mouse chromosome 3 between
the loxP sites was removed by Cre-mediated recombina-
tion. Hemizygotic embryonic stem cells were injected into
blastocysts isolated from impregnated BALB/c female
mice and transferred to pseudopregnant NMRI female
mice. Chimeric male pups were selected by coat color and
mated with wild-type C57BL/6 female mice. Finally, a
chimera with germline transmission was selected for
expansion breeding (see Supplemental Methods).
All studies were carried out in accordance with Danish
legislation, granted by the animal welfare committee,
appointed by the Danish Ministry of Food, Agriculture
and Fisheries–Danish Veterinary and Food Administra-
tion. Animals were bred by mating wild-type C57BL/6N
female mice with hemizygotic Df(h1q21)/+ male mice to
avoid any placental or maternal care effects of the dele-
tion. After weaning at 3 weeks, tail biopsies were collected
for polymerase chaine reaction-based genotyping (Sup-
plemental Methods). Mice were then group-housed (two
wild-type mice and two hemizygotes from the same litter
per cage). Testing was conducted using 9–13-week-old
male mice. Animals were randomized into dose groups
where appropriate, dependent on genotype. Experi-
menters were blinded to genotype in all non-automated
assays.
Drugs
Phencyclidine hydrochloride (PCP, Sigma-Aldrich,
Denmark), amphetamine (Dexamphetamine, Fagron, UK),
apomorphine hydrocloride (Sigma-Aldrich), and quin-
pirole hydrocloride were all dissolved in 0.9% saline and
pH-adjusted where appropriate. SKF-81297 hydro-
bromide (synthesized at Lundbeck) was dissolved in iso-
tonic water with 5% glucose and pH-adjusted.
Compounds were injected subcutaneously at a volume of
10ml/kg.
Baseline and psychostimulant-induced activity
For baseline activity, mice were placed individually in
Macrolon locomotor activity cages (20 cm× 35 cm× 18
cm, Ellegaard Systems, Denmark) containing an in-
chamber activity wheel (Med Associates, USA). Cages
were equipped with two rows of 5× 8 infrared light
sources and photocells. Locomotor activity, rearing and
running wheel revolutions were recorded for 24 h.
For psychostimulant-induced activity, mice were placed
in similar cages with one row of photo beams and no
running wheel, and were allowed to habituate for 60min.
Then vehicle, d-amphetamine, or PCP was administered
and locomotor activity was recorded for an additional 60
min. To avoid stationary movement artifacts, motility
counts required two consecutive crossings of adjacent
infrared light beams. Registration and timing of loco-
motor activity was fully automated (custom-designed
hardware and software by Ellegaard Systems).
Apomorphine-induced climbing
Each mouse was habituated to a small Macrolon cage
without bedding for 1 h. Apomorphine was administered
15min prior the test. Mice were then singly placed in a
mesh cylinder (height 14 cm, diameter 13 cm) with a top
cover, and time on mesh walls with two or more paws was
measured for 120 s.
Prepulse inhibition
Prepulse inhibition (PPI) testing was performed using
the SM100 Startle Monitor System (Kinder Scientiﬁc,
USA), consisting of eight sound-attenuated startle
chambers and Startle Monitor software. Animals were
placed in an adjustable Plexiglas holder, providing limited
movement but not restraint, positioned directly above a
sensing platform. Each test session consisted of 5 min
acclimatization with only background white noise (62 dB),
followed by habituation with 32 startle pulses of 105 dB
(intertrial interval (ITI): 10 s). Animals were then sub-
jected to ﬁve types of trials presented 12 times each in a
balanced manner: pulse alone, prepulse+ pulse (5, 10, or
15 dB above background), or highest prepulse intensity
(77 dB) alone. ITI varied from 9 to 21 s (average 15),
interstimulus interval was 100ms, prepulse length 20 ms,
and pulse length 30ms. Each PPI session ended with eight
startle pulses of 105 dB to estimate habituation across PPI
trials. The full PPI test lasted about 28min.
PPI was calculated as % PPI for each prepulse intensity
as: 100−((prepulse+ pulse/pulse_alone)× 100); lower
percentage indicates decreased PPI. Startle magnitude was
calculated from average of pulse alone trials.
Ex vivo measurement of DA receptor levels by radio-ligand
binding to homogenized striatal tissue
Whole striati were homogenized in 1ml 0.4M sucrose
and centrifuged at 4 °C for 10min at 1000×g. The
supernatant was transferred to a fresh tube and cen-
trifuged at 4 °C for 30 min at 40,000×g. The supernatant
was discarded and the pellet was re-suspended in 0.5 ml
0.4M sucrose and protein concentration was measured
using a Pierce BCA kit (ThermoFischer, USA).
Binding experiments were performed in a total volume
of 200 μl, where 40 μg of homogenate was mixed with
either 1 nM 3H-SCH-23390 for D1 (PerkinElmer,
NET930) or 0.5 nM 3H-spiperone for D2 (PerkinElmer,
NET565) in binding buffer (50 mM Tris pH 7.4, 120mM
NaCl, 4 mM MgCl2, 5 mM KCl, 1 mM EDTA). Non-
speciﬁc binding was determined by further addition of 10
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μM Flupentixol (for D1) or 10 μM Haloperidol (D2).
Binding mixtures were incubated for 30min at 37 °C
before bound ligand was separated by ﬁltration (Packard
GF/C uniﬁlter) on a Tomtec Harvester (96® Mach-3u,
Tomtec, USA). Filters were washed twice with 0.5 mL ice-
cold 50 mM Tris pH 7.7. Filters were dried for 20 min (37
°C) before addition of OptiPhase SuperMix (Perkin Elmer)
and counted in a MicroBeta® TriLux (Perkin Elmer)
counter for 5 min.
Individual homogenates from six wild-type and six
transgenic mice were used to determine D1 and D2 binding
in two independent experiments performed in duplicates.
Speciﬁc binding of Df(h1q21)/+ mice was normalized to
the average speciﬁc binding of wild-type mice.
In vivo voltammetry
Mice were anesthetized by intraperitoneal injection of
chloral hydrate (450 mg/kg; Sigma-Aldrich, USA) sup-
plemented by a dose of 100mg/kg every 45–60min.
Rectal temperature was monitored and maintained at 37 °
C using a heating lamp. Animals were ﬁxed in a stereo-
taxic frame (David Kopf Instruments, USA). Openings
were made in the skull and a carbon ﬁber working elec-
trode (32 µm diameter, 300 µm exposed length) was
inserted into the nucleus accumbens (coordinates: 1.42
mm anterior to bregma, 1.0 mm lateral to the midline, and
4.5 mm ventral to the cortical surface)19. A bipolar sti-
mulating electrode (diameter 0.35 mm) was inserted into
the medial forebrain bundle (MFB; 1.6 mm posterior to
bregma, 1.1 mm lateral to the midline, and 5.1–5.3 mm
ventral to the cortical surface). The depth of the stimu-
lating electrode was adjusted to evoke maximal DA
release. An Ag/AgCl reference electrode was placed on
the skull via a saline bridge.
Fast scan cyclic voltammetry was performed and data
were analyzed with Invilog Voltammetry Setup (Invilog
Research, Finland). The applied potential of a triangular
waveform was ramped up from −0.4 to 1.2 V and back to
−0.4 V at a scan rate of 300 V/s vs. an Ag/AgCl reference
electrode. At the end of the experiment, the location of
the working electrode was marked by an electrolytic
lesion (6 V, 10 s) for histological visualization.
The MFB was stimulated by 1ms bipolar 200–300 µA
pulses. Frequency–response curves were established for
each animal using consecutive bursts of 50 pulses at 10,
20, 30, and 50 Hz applied to the MFB with 1–4min
intervals. Efﬁciency of DA reuptake was evaluated by
measuring the half-width of the descending part of DA
overﬂow peaks of comparable heights (<0.5 μM). Auto-
inhibition of DA release was assessed by applying paired
stimuli (5 bipolar 100 Hz pulses) at variable intervals of
0.5–5 s, and expressed as percentage of the amplitude of
DA overﬂow evoked by the second relative to the ﬁrst
stimulus.
In vivo microdialysis
Mice were anesthetized with sevoﬂurane and intracer-
ebral guide cannulas (040, Brainlink, the Netherlands)
were stereotaxically implanted into the nucleus accum-
bens (coordinates: 1.1 mm anterior to bregma, lateral 1.5
mm, and 3.4 mm ventral to dura)19. Anchor screws and
acrylic cement were used for ﬁxation of the guide can-
nulas. The body temperature of the animals was mon-
itored by rectal probe and maintained at 37 °C. Mice were
allowed to recover from surgery for 1 day, housed indi-
vidually in cages. On the day of the experiment, a
microdialysis probe (Brainlink, PAN 060-10, 1 mm
length) was inserted through the guide cannula. Probes
were connected via a dual channel swivel to a micro-
injection pump. Perfusion of the microdialysis probe with
ﬁltered Ringer solution (145 mm NaCl, 3 mM KCl, 1 mM
MgCl2, 1.2 mM CaCl2) was begun shortly before insertion
of the probe into the brain and continued for the duration
of the experiment at a constant ﬂow rate of 1 μl/min.
Dialysates were collected every 20min. After the experi-
ments, brains were removed and probe placement ver-
iﬁed. Perfusion for 180min was followed by collection of
four basal fractions and six post-injection fractions. DA in
the dialysates was analyzed by HPLC with electrochemical
detection, as described previously20.
In vivo electrophysiology
Animals were anesthetized with an intraperitoneal
injection of urethane (1.2–1.5 g/kg), mounted in a ste-
reotaxic frame and their temperature was adjusted to 37.5
°C by a heating pad. A hole was drilled above the ventral
tegmental area (VTA). Extracellular single-cell recordings
were performed using electrodes pulled from glass capil-
laries and ﬁlled with 2% Pontamine Sky Blue in 0.5M
sodium acetate (impedance 2.0–8.0MΩ at 135 Hz). The
electrode was lowered to the dorsal border of the VTA,
and then advanced at a slow (1–3 µm/s), uniform speed
using a microdrive. Extracellular action potentials were
ampliﬁed, discriminated, and monitored on an oscillo-
scope and an audiomonitor.
To assess basal ﬁring properties of DA neurons in the
VTA, the number of spontaneously active DA neurons
was determined in six to nine stereotaxic descents sepa-
rated from each other by 150–200 µm. Descents were
made in a stereotaxically deﬁned block of tissue within the
VTA area (3.4–3.0 mm posterior to bregma, 0.3–0.6 mm
lateral to the midline, and 3.8–5.0 mm ventral to the
cortical surface)19.
Presumed dopaminergic neurons were characterized by
a slow and irregular ﬁring pattern (0.5–10 Hz), and tri-
phasic action potentials with a predominant positive
component, a negative component followed by a minor
positive component, with an overall duration >2.5 ms21.
The number of spontaneously active DA neurons was
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counted. Each neuron was recorded for 2–5min for off-
line analysis of their basal ﬁring rate, and the coefﬁcient of
variation of the interspike interval deﬁned as the ratio
between the average interspike interval and the SD of the
interspike interval× 100. In addition, the neuronal dis-
charge pattern of each neuron was classiﬁed as regular,
irregular, or bursty based on autocorrelograms as
described previously22,23.
The effect of d-amphetamine or quinpirole on neuronal
ﬁring rate was assessed in a single neuron per animal.
Once a DA neuron was isolated and had a stable ﬁring
rate for a minimum of 200 s, a single saline injection was
performed subcutaneously (5 ml/kg), followed by three
consecutive injections of either d-amphetamine (1.25, 2.5,
and 5mg/kg) or quinpirole (0.05, 0.10, and 0.20 mg/kg)
separated by 15min. The effect of vehicle and drugs was
normalized to the baseline ﬁring rate.
Data and statistical analysis
Sample sizes were based on established practice in
respective assays, and to some extent determined by
breeding availability. Statistical analysis was performed
using SigmaPlot 11.0 (Systat Software, USA) or Prism 5
(GraphPad Software, USA). Distribution of DA neuron
ﬁring patterns was and using the Χ2-test. All other data
were analyzed by either two-way analysis of variance
(ANOVA), two-way mixed-model ANOVA, or by t-test.
Where appropriate, t-test was replaced with
Mann–Whitney rank sum test. Post hoc tests following
ANOVAs were conducted using Bonferroni correction.
Two-tailed levels of signiﬁcance were used and p< 0.05
was considered statistically signiﬁcant.
Results
Generation of Df(h1q21.1)/+ mice and expression of
targeted genes
Mouse orthologs of the human 1q21.1 genes are located
on mouse chromosome 3F2.2 (Fig. 1a). A mouse model of
the human 1q21.1 microdeletion syndrome (Df(h1q21.1)/
+) was generated by deleting the corresponding region on
mouse chromosome 3qF2.2 through Cre-mediated
recombination. Pups were born at the expected ratios
(hemizygous fraction 0.49, 95% conﬁdence interval:
0.41–0.56, n= 179).
Expression of 1q21.1 genes was examined by microarray
analysis of RNA from the cerebral cortex (Fig. 1b). Except
for the olfactory receptor gene Olfr1402, all detected
genes in the deleted region showed signiﬁcant down-
regulation to roughly 50% of the expression in wild-type
mice. Cortical RNAseq data from wild-type mice did not
detect any Olfr1402 transcript, suggesting that the
apparently unchanged Olfr1402 expression reﬂects false
detection in the microarray experiment (data not shown).
Expression of one ﬂanking gene, Pdzk1, was also reduced
by 50% in Df(h1q21)/+ mice.
Df(h1q21.1)/+ mice are shorter than wild-type mice similar
to human deletion carriers
Short stature has been reported as a common pheno-
type of the human 1q21.1 microdeletion13,14, and we
therefore measured the length of adult Df(h1q21)/+ mice.
Like the reported short stature of human carriers, Df
(h1q21)/+ mice were shorter than wild-type littermates
(p< 0.001, Fig. 1c).
Adult Df(h1q21)/+ mice had grossly normal behavior
and appearance, but were slightly lighter than wild-type
littermates (wild-type 24.2± 0.1 g, n= 233; Df(h1q21)/
+23.0± 0.1 g, n= 235; t-test, p< 0.0001). We found no
alterations in gross brain morphology, myelination, and
parvalbumin-positive interneuron counts (Supplementary
Fig. S1).
Df(h1q21)/+ mice exhibit increased sensitivity to
psychostimulants
Df(h1q21)/+ mice were examined in a broad behavioral
test battery focusing on schizophrenia-related traits, but
also including measures of motor performance, pain
sensitivity, anxiety, and seizure threshold (see Supple-
mentary Table S1 for an overview of assays and results).
The Df(h1q21)/+ mice were indistinguishable from wild-
type littermates in most assays in this test battery with two
exceptions: slightly reduced activity in 24-h running wheel
(Supplementary Fig. S2a) and altered psychostimulant
response as detailed below.
Following amphetamine administration, the locomotor
response of Df(h1q21)/+ mice was different from that of
wild-type littermates (p< 0.001, Fig. 2a). Df(h1q21)/+
mice showed an increased response to 2.5 mg/kg of
amphetamine (p < 0.001) and a decreased activity at 5 mg/
kg amphetamine (p< 0.05), likely due to increased ste-
reotypy at this dose. The increased locomotor response to
2.5 mg/kg amphetamine was subsequently conﬁrmed in
an independent experiment (Supplementary Figs. S2b, c).
Following PCP administration, the locomotor response
of Df(h1q21)/+ mice was not signiﬁcantly different from
wild types (Fig. 2b). We also assessed basal and
psychostimulant-disrupted acoustic startle response
(ASR) and PPI. Basal ASR at various sound intensities
(95–120 dB) was unaltered in Df(h1q21)/+ mice (Sup-
plementary Fig. S3a). Similarly, since basal PPI was not
affected by genotype (Supplementary Fig. S3b), and no
genotype × prepulse intensity interaction was observed,
only drug-treated groups were included in the analyses of
the following psychostimulant experiments, and PPI was
collapsed across prepulse intensities.
Amphetamine treatment decreased PPI more in Df
(h1q21)/+ than in wild-type mice (p < 0.05, Fig. 2c),
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indicating an increased sensitivity to the disruptive effect
of amphetamine on PPI as well. The increased PPI sen-
sitivity to 2.5 mg/kg amphetamine was subsequently
replicated in a separate batch of animals (Supplementary
Fig. S4c). Amphetamine decreased ASR to a similar extent
in both genotypes (Supplementary Fig. S4f). In contrast to
the locomotor assay, Df(h1q21)/+ mice were signiﬁcantly
more sensitive to PCP-induced disruption of PPI than
wild types (p < 0.001, Fig. 2d), which was driven by the
2.5 mg/kg PCP dose (p < 0.001, Fig. 2d). The effect of PCP
on ASR was not different between the two genotypes (data
not shown).
Because of the increased amphetamine sensitivity found
in the Df(h1q21)/+ mice, we also measured the brain and
blood exposure of amphetamine in the mice 1 h after
administration. There were no differences in the brain or
plasma levels of amphetamine between genotypes (Sup-
plementary Fig. S6).
Sensitivity of Df(h1q21)/+ mice to D1 and D2 receptor
agonists and expression of DA receptors
The increased amphetamine sensitivity of Df(h1q21)/+
mice suggests altered dopaminergic signaling in the basal
ganglia, and we therefore investigated post-synaptic and
pre-synaptic functions in more detail.
First, we assessed potential post-synaptic effects of the
deletion using DA receptor agonists. The locomotor
response to the D1 agonist SKF-81297 was similar in Df
(h1q21)/+ and wild-type mice (Fig. 3a, b). D2 signaling
was then probed by administering the D2/D3 agonist
quinpirole and assessing its effects on horizontal activity.
Initially, quinpirole strongly decreased activity similarly in
both genotypes, presumably because of activation of pre-
synaptic autoreceptors (Fig. 3d). As expected, a putatively
post-synaptic D2-dependent increase in locomotor activ-
ity was seen around 30min after quinpirole administra-
tion (Fig. 3d). This late increase in activity has been
hypothesized to primarily reﬂect post-synaptic D2 acti-
vation24, and this increase was signiﬁcantly bigger in Df
(h1q21)/+ mice compared to wild types (p< 0.01, Fig. 3e).
Similarly, administration of the non-selective DA agonist
apomorphine caused a signiﬁcantly higher degree of
climbing behavior in Df(h1q21)/+ mice at 0.2 mg/kg (p<
0.01, Fig. 3c) but not at 0.3 mg/kg.
To investigate whether DA receptor levels were altered,
we measured binding of tritiated D1 and D2 receptor
ligands to striatal membranes from these mice ex vivo
Fig. 2 Psychostimulant-induced behavioral alterations in Df(h1q21)/+ mice. a Horizontal activity following amphetamine (AMPH) treatment
(0–5 mg/kg). Genotype × treatment interaction, F3,88 = 11.15, p < 0.001, n = 11–12/group. For full time curve see Supplementary Fig. S3A. b Horizontal
activity following phencyclidine (PCP) treatment (0–5 mg/kg). n = 12/group. No signiﬁcant differences between genotypes. For full time curve see
Supplementary Fig. S3B. c Prepulse inhibition (PPI) following AMPH treatment. Effect of genotype, F1,64 = 4.50, p < 0.05, n = 11–12/group. d Prepulse
inhibition (PPI) following PCP treatment. Effect of genotype, F1,61 = 12.05, n = 10–12/group. Data sets were analyzed by two-way ANOVA with post
hoc comparisons using Bonferroni correction where appropriate. Stars in the upper right corner of ﬁgures represent main effect of genotype, while
stars above columns represent Bonferroni-corrected post hoc tests. Data presented as means ± SEM. *p < 0.05; ***p < 0.001 vs. wild types. Dotted lines
in c, d symbolize exclusion of vehicle-treated animals from statistical analyses (see Results section)
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(Fig. 3f). There was no difference in D1 and D2 receptor
levels between the genotypes, indicating that changes in
receptor expression level are unlikely to explain the dif-
ferences in behavioral response.
Stimulated DA release, reuptake, and autoinhibition in the
nucleus accumbens of Df(h1q21)/+ mice
Putative pre-synaptic alterations in DA release and
reuptake were assessed by in vivo voltammetry.
Electrical stimulation of the MFB using a burst of 50
pulses increased extracellular DA concentrations in the
nucleus accumbens in a frequency-dependent, nonlinear
manner. This nonlinear relationship between frequency of
stimulation and peak DA overﬂow is suggested to result
from a shift of the balance between release and reuptake
mechanisms toward dominance of release at higher sti-
mulation frequency25, and it was not altered in Df(h1q21)/
+ mice (p= 0.53, Fig. 4a).
Efﬁciency of DA reuptake was assessed by measuring
the half-width of the descending slope of the peak DA
overﬂow evoked at low frequencies of stimulation where
uptake mechanisms are not saturated (peak DA con-
centrations below 0.5 µM)26. It was not signiﬁcantly dif-
ferent in Df(h1q21)/+ and wild-type mice (p= 0.16,
Fig. 4b).
Autoinhibition of DA release mediated by pre-synaptic
D2 autoreceptors was evaluated by a paired-pulse stimu-
lation protocol27. The interval between the two stimuli
was negatively correlated to the autoinhibition, i.e., the
shorter the interval, the larger the inhibition of the second
DA overﬂow peak (Fig. 4c). Autoinhibition of DA release
was not signiﬁcantly different in Df(h1q21)/+ mice
compared to wild-type mice (p= 0.13, Fig. 4c).
d-amphetamine-induced DA efﬂux in the nucleus
accumbens of Df(h1q21)/+ mice
Extracellular DA levels in the nucleus accumbens were
assessed by microdialysis. Basal DA levels without con-
sidering probe recovery were 7.7± 2.2 in wild type (n= 6)
and 12.2± 3.8 (n= 11) fmol/20 µl in Df(h1q21)/+, and
were not signiﬁcantly different between genotypes (p=
0.96).
Injection of d-amphetamine induced DA efﬂux reaching
a maximum 20min following administration in both wild-
type and Df(h1q21)/+ mice (Fig. 4d). There was no sig-
niﬁcant difference between genotypes (p= 0.52).
Basal ﬁring properties of DA neurons in the ventral
tegmental area of Df(h1q21)/+ mice
Firing properties of DA neurons were assessed in the
VTA of Df(h1q21)/+ (six mice, 84 neurons) and wild-type
Fig. 3 D1-dependent and D2-dependent changes in Df(h1q21)/+ mice. a Horizontal activity (in 5 min bins) following treatment with D1 agonist
SKF-81297 (0.49 and 2 mg/kg). n = 7–8/group. Shaded area representing bins used for quantiﬁcation. b Horizontal activity summary for 60–120 bins in
(a). c Climbing duration following two doses of apomorphine (0.2 and 0.3 mg/kg). ##p < 0.01 following Mann–Whitney test with Bonferroni
correction. d Horizontal activity (in 5 min bins) following treatment with D2 agonist quinpirole (0.75 and 3 mg/kg). n = 7–8/group. e Horizontal
activity summary for 50–60 bins in (d; effect of genotype following mixed model ANOVA). f Normalized D1-speciﬁc and D2-speciﬁc binding using
striatal membranes. n = 11–12/group. Stars above columns represent post hoc tests and stars in the upper right corner of ﬁgures represent main
effect of genotype. Data presented as means ± SEM. **p < 0.01
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(ﬁve mice, 57 neurons) mice. The average number of
spontaneously active DA neurons per track was increased
in Df(h1q21)/+ mice (p= 0.028, Fig. 5a). The average
ﬁring rate of all recorded DA neurons was not sig-
niﬁcantly different in Df(h1q21)/+ mice (3.64± 0.30 Hz)
compared to wild-type mice (4.04± 0.32 Hz; p= 0.18,
data not shown). The coefﬁcient of variation of the
interspike interval was signiﬁcantly higher in Df(h1q21)/+
mice compared to wild-type mice (p= 0.012, Fig. 5b).
Further classiﬁcation of the ﬁring pattern into regular,
irregular, or bursty, for all recorded neurons showed that
Df(h1q21)/+ mice exhibited a signiﬁcantly different dis-
tribution of the different ﬁring patterns compared to wild-
type mice (p< 0.001, Fig. 5c), with a higher proportion of
bursty neurons.
d-amphetamine and quinpirole-induced inhibition of DA
ﬁring activity in Df(h1q21)/+ mice
Administration of d-amphetamine to wild-type mice
induced a dose-dependent inhibition of DA cell ﬁring rate
in the VTA compared to vehicle administration (p<
0.001). Although dose-dependent inhibition was also
observed in Df(h1q21)/+ mice, the suppressive effect of d-
amphetamine was reduced compared to wild-type mice
(p< 0.001, Fig. 5d).
Administration of quinpirole to wild-type mice induced a
dose-dependent inhibition of DA cell ﬁring rate in the VTA
compared to vehicle administration (p< 0.001), which was
not signiﬁcantly altered in Df(h1q21)/+ mice (p= 0.72).
Discussion
In this paper, we describe the generation and char-
acterization of the ﬁrst mouse model of the
schizophrenia-associated 1q21.1 CNV. Df(h1q21)/+ mice
exhibited increased response to psychostimulants and
altered DA transmission. These changes were relatively
speciﬁc, as the mice were otherwise indistinguishable
from wild-type mice in a broad panel of behavioral tests.
The Df(h1q21)/+ phenotype recapitulates key aspects of
the DA hypothesis of schizophrenia, making it a pro-
mising model for investigation of schizophrenia-related
alterations of DA transmission.
Fig. 4 Dopamine (DA) homeostasis in the nucleus accumbens of Df(h1q21)/+ and wild-type (WT) mice. a DA overﬂow (µM), determined by
voltammetry, in response to increased frequency of MFB stimulation (10–50 Hz) was not different between genotypes (two-way ANOVA with
repeated measurements, F(1,42) = 0.43, p = 0.53, n = 8–9). Insert: representative examples of DA overﬂow in response to four different stimulation
frequencies. b DA reuptake was evaluated by measuring the half-width of descending part of the overﬂow curves at low frequencies of stimulation
(10–30 Hz), and was not signiﬁcantly different between genotypes (unpaired t-test, p = 0.16, n = 7–8). c Autoinhibition of DA release was evaluated by
application of two consecutive stimuli (interval 0.5 – 5.0 s), and was not signiﬁcantly different between genotypes (two-way ANOVA with repeated
measurements, F(1,75) = 2.64, p = 0.13, n = 7–8); the amplitude of DA overﬂow evoked by the second stimulation (p2, insert) was expressed as
percentage of the response evoked by the ﬁrst stimulation (p1, insert). d The effect of d-amphetamine (2.5 mg/kg, s.c.) on DA efﬂux in the nucleus
accumbens (fmol/20 µl) was investigated in both genotypes using in vivo microdialysis (two-way ANOVA with repeated measurements, F(1,60) = 0.43,
p = 0.52, n = 6–11)
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In addition to the altered brain function, the Df(h1q21)/
+ mice exhibited reduced head-to-tail length. Short sta-
ture is observed in human subjects with 1q21.113,14, fur-
ther supporting the translational potential of the model.
DA phenotype
Df(h1q21)/+ mice were hypersensitive to the DA-
releasing drug amphetamine in locomotor as well as PPI
experiments. In addition, they were hypersensitive to the
NMDA receptor antagonist PCP in the PPI test. Since
altered psychostimulant sensitivity and DA metabolism
are among the best validated observations in schizo-
phrenia, these changes support the schizophrenia rele-
vance of the Df(h1q21)/+ model—particularly with
respect to positive symptoms, which are most convin-
cingly linked to DA transmission1. Thus, the Df(h1q21)/+
mice provide an opportunity to study changes in DA
transmission in a genetically relevant schizophrenia
model.
Further examination of post-synaptic DA function
revealed that striatal DA receptor levels and D1 signaling
were unaffected in Df(h1q21)/+ mice, while their sensi-
tivity to D2 agonists and mixed D2/D1 agonists was
increased. This might indicate that post-synaptic
D2 signaling is altered, although the effect may also be
mediated by pre-synaptic D2 autoreceptors.
Evaluation of pre-synaptic DA function based on DA
levels in the nucleus accumbens and in vivo voltammetry
indicated that release and reuptake capacity were unal-
tered in Df(h1q21)/+ mice. In contrast, DA neuron ﬁring
in the VTA was altered in Df(h1q21)/+ mice with more
spontaneously active cells and increased ﬁring variability.
Furthermore, attenuated inhibition of ﬁring in response to
amphetamine was seen in Df(h1q21)/+ mice—ampheta-
mine releases DA by ﬁring-independent mechanisms
Fig. 5 Electrophysiological properties of dopaminergic neurons in the VTA of Df(h1q21)/+ and wild-type (WT) mice. a The number of
spontaneously active DA cells per track was signiﬁcantly higher in Df(h1q21)/+ compared to wild-type mice (unpaired t-test, p = 0.028, n = 57–84). b
Spike trains for all active neurons in each genotype were analyzed to calculate the coefﬁcient of variation of the interspike interval (ISI), which was
signiﬁcantly higher in Df(h1q21)/+ compared to wild-type mice (unpaired t-test, p = 0.012, n = 57–84). c The ﬁring pattern was classiﬁed as regular,
irregular, or bursty for each neuron recorded, and a signiﬁcantly different distribution was present in Df(h1q21)/+ compared to wild-type mice (Χ2-
test, p < 0.001, n = 57–84). d The effect of d-amphetamine on DA cell ﬁring rate was evaluated by administration of increasing doses of d-
amphetamine (1.25, 2.5, and 5 mg/kg i.v.) following a single vehicle injection (NaCl 0.9%, i.v.); a signiﬁcant difference in the dose-dependent inhibition
was observed between genotypes (two-way ANOVA with repeated measurements, F(1,32) = 27,31, p < 0.001, n = 5–9). e The effect of quinpirole on DA
cell ﬁring rate was evaluated by administration of increasing doses of quinpirole (0.05, 0.10, and 0.20 mg/kg i.v.) following a single vehicle injection
(NaCl 0.9%, i.v.); no signiﬁcant difference in the dose-dependent inhibition was found between genotype (two-way ANOVA with repeated
measurements, F(1,23) = 0.159, p = 0.69, n = 4–8). *p < 0.05; ***p < 0.001
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leading to inhibition of DA neuron ﬁring through soma-
todendritic D2 autoreceptors and accumbal feedback
pathways28. Our ﬁndings therefore indicate altered feed-
back regulation of DA cell ﬁring in Df(h1q21)/+ mice
compared to wild types. Changes in D2 autoreceptor
function are unlikely, since the D2 agonist quinpirole
inhibited DA cell ﬁring equally in both genotypes, a
mechanism known to involve somatodendritic auto-
receptors29. Furthermore, autoreceptors located on
dopaminergic terminals in the nucleus accumbens were
not functionally different in Df(h1q21)/+ mice compared
to wild types as shown by the comparable paired-pulse
depression of DA release. Alternatively, reduced feedback
regulation of DA neuron ﬁring may increase the number
of spontaneously active dopaminergic neurons through
reduced GABAergic tone in the VTA21,30. This could in
turn increase their sensitivity to excitatory inputs and
exacerbate burst ﬁring, as observed in the present study.
However, the increased population activity and burst ﬁr-
ing did not result in a signiﬁcant increase in extracellular
DA in nucleus accumbens. Similar apparent discrepancies
have been found in other studies30,31. Possible explana-
tions include different sensitivity of dopaminergic systems
in anesthetized vs. awake32,33, and a minor effect of burst
ﬁring on tonic DA30. Furthermore, DA levels that are too
small to be robustly detected by microdialysis may con-
tribute to the behavioral phenotypes, and compensatory
changes occluding an effect on DA release might occur.
We focused on the mesolimbic pathway, but meta-
analysis of human imaging data suggests that pre-
synaptic hyperdopaminergia in schizophrenia is more
prominent in associative striatum8. Conceivably, dopa-
minergic alterations in Df(h1q21)/+ mice could be more
prominent there, and dopaminergic signaling in associa-
tive striatum should be tested in future studies.
In summary, the altered DA cell ﬁring activity clearly
supports a pre-synaptic DA dysfunction in Df(h1q21)/+
mice, but other observations such as unchanged extra-
cellular DA levels and the behavioral effect of a D2 agonist
suggest that there are other, possibly compensatory,
changes in the Df(h1q21)/+ DA system. Further studies,
including investigations of more dorsal parts of the
striatum, are needed to expand the understanding of
mechanisms underlying the altered psychostimulant
response and DA transmission in Df(h1q21)/+ mice.
Comparison to other animal models of schizophrenia
Psychostimulant sensitivity has been examined for two
other mouse models of schizophrenia-associated CNVs:
the 15q13.3 and the 22q11.2 microdeletions34–36. While
these two models had speciﬁc phenotypes that might relate
to schizophrenia, neither of them had altered amphetamine
sensitivity, but the 22q11.2 model had increased sensitivity
to PCP similar toDf(h1q21)/+mice and slightly altered DA
metabolism in the cortex34,36. This suggests that these
chromosomal deletions provoke a complex pattern of
partly overlapping, partly distinct neurophysiological per-
turbations that predispose to severe mental illness. Argu-
ably, this is not surprising, given the partial penetrance of
such deletions in humans. Furthermore, there are transla-
tional challenges including species differences in brain
biology and behavior, suppressant effects of genetic back-
ground and age-dependent appearance of phenotypes37.
Thus, the models may be reliable models of the human
CNVs but cannot be considered to be genuine schizo-
phrenia or disease models, but rather as complementary
models of liability to mental disorders. It may be possible to
strengthen penetrance in models by introducing second
hits, e.g., by testing CNV models in different strains that
may be more susceptible or combining a CNV model with
an environmental challenge. We only proﬁled male mice to
reduce variability and increase power. Female mice should
also be examined in future studies.
Several of the so-called neurodevelopmental schizo-
phrenia models based on developmental challenge have
altered psychostimulant response38. The methylazox-
ymethanol (MAM) model, where rats are exposed to
MAM in utero at embryonic day 17, is the best char-
acterized of those with regard to DA transmission39,40.
Like the Df(h1q21)/+ mice, MAM rats have increased
locomotor response to amphetamine and VTA popula-
tion activity at baseline41,42. However, no change in burst
ﬁring was reported in the MAM model. Hyperactivity of
the ventral subiculum has been suggested to cause a
hyperdopaminergic state in MAM rats41,42, and it would
be relevant to investigate whether similar changes occur
in Df(h1q21)/+ mice.
Gene contributions
Nine genes are hemizygously deleted in the 1q21.1
microdeletion (Fig. 1). Our characterization of Df(h1q21)/
+ mice allows investigation of the contribution of the
individual genes to altered DA transmission by compar-
ison with mice with hemizygous deletion of individual
genes. Mice with homozygous deletion of the Prkab2,
Fmo5, Gja5, and Gja8 genes have been reported43–46.
However, none of these studies have tested amphetamine
sensitivity of mice with homozygous or hemizygous
deletions, leaving this comparison to future work.
Perspectives
In conclusion, we have generated and characterized the
ﬁrst mouse model of the schizophrenia-associated human
1q21.1 microdeletion syndrome, which we show have
altered DA signaling and psychostimulant sensitivity as
also observed in patients with schizophrenia. The limited
similarity of available genetic schizophrenia models
highlights that many paths may lead to schizophrenia, and
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further the need to characterize and compare different
models to understand the convergence to the symptoms
of schizophrenia. In this context, an improved description
of the schizophrenia symptomatology associated with the
individual genetic variants would be of great importance
—e.g., whether schizophrenia patients with 1q21.1
microdeletion predominantly display positive symptoms.
The perturbations of Df(h1q21)/+ mice demonstrated
here appear to primarily affect the DA system, and par-
ticularly D2 receptor-mediated transmission. As this
receptor serves as a common target for all existing anti-
psychotics, the Df(h1q21)/+ model may prove to be par-
ticularly useful for the investigation of mechanisms
underlying positive symptoms and the associated aberrant
DA transmission observed in schizophrenia.
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